18-Sep-2026
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 9-Sep 8:00 AM ET)
Globe Newswire (Thu, 6-Aug 8:00 AM ET)
Pacira BioSciences Reports Second Quarter 2026 Financial Results
Globe Newswire (Tue, 4-Aug 4:01 PM ET)
Globe Newswire (Tue, 28-Jul 8:00 AM ET)
Globe Newswire (Mon, 27-Jul 8:00 AM ET)
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
Globe Newswire (Wed, 22-Jul 8:00 AM ET)
Market Chameleon (Wed, 1-Jul 4:58 AM ET)
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL
Globe Newswire (Wed, 1-Jul 8:00 AM ET)
Pacira BioSciences Announces Agreement to Divest its iovera Business to Zimmer Biomet
Globe Newswire (Tue, 30-Jun 7:30 AM ET)
Pacira BioSciences Grants Over 36,000 Options and 27,000 RSUs in Strategic Talent Investment
Market Chameleon (Fri, 8-May 5:24 AM ET)
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Pacira Biosciences trades on the NASDAQ stock market under the symbol PCRX.
As of September 18, 2026, PCRX stock price climbed to $24.69 with 605,368 million shares trading.
PCRX has a beta of 0.02, meaning it tends to be less sensitive to market movements. PCRX has a correlation of 0.00 to the broad based SPY ETF.
PCRX has a market cap of $984.19 million. This is considered a Small Cap stock.
Last quarter Pacira Biosciences reported $192 million in Revenue and $.73 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.16.
In the last 3 years, PCRX traded as high as $35.95 and as low as $11.16.
The top ETF exchange traded funds that PCRX belongs to (by Net Assets): IJR, VTI, IWM, VB, AVUV.
PCRX has underperformed the market in the last year with a price return of -7.4% while the SPY ETF gained +16.8%. However, in the short term, PCRX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +10.6% vs +2.3% return in SPY. But in the last 2 weeks, PCRX shares have been beat by the market, returning -6.3% compared to an SPY return of -0.9%.
PCRX support price is $23.96 and resistance is $25.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PCRX shares will trade within this expected range on the day.